Stockscreener 앱 받기
15.04
1.07%
0.145
전일 마감가:
$14.89
열려 있는:
$14.92
하루 거래량:
190.24K
Relative Volume:
0.24
시가총액:
$1.11B
수익:
$97.36M
순이익/손실:
$-172.42M
주가수익비율:
-6.5415
EPS:
-2.2984
순현금흐름:
$-188.84M
1주 성능:
-6.52%
1개월 성능:
+27.87%
6개월 성능:
+0.67%
1년 성능:
+89.55%
1일 변동 폭
$14.72
$15.35
1주일 범위
$14.61
$16.10
52주 변동 폭
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
명칭
Xencor Inc
전화
626-305-5900
주소
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
15.02 | 1.11B | 97.36M | -172.42M | -188.84M | -2.2984 |
VRTX
Vertex Pharmaceuticals Inc
|
524.50 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.75 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
923.41 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.24 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.70 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-10-29 | 업그레이드 | Barclays | Underweight → Overweight |
| 2025-09-17 | 재개 | Barclays | Underweight |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-04-21 | 개시 | William Blair | Outperform |
| 2024-12-12 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | 재확인 | BTIG Research | Buy |
| 2024-02-28 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | 개시 | BofA Securities | Buy |
| 2022-12-06 | 개시 | Cowen | Outperform |
| 2022-10-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-21 | 개시 | SMBC Nikko | Outperform |
| 2021-12-15 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-02-24 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | 개시 | Barclays | Underweight |
| 2020-02-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-01-30 | 개시 | RBC Capital Mkts | Outperform |
| 2019-11-20 | 재개 | Guggenheim | Neutral |
| 2019-08-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-08-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-04-12 | 개시 | Guggenheim | Buy |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2019-03-15 | 개시 | Raymond James | Outperform |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2017-03-02 | 개시 | Instinet | Neutral |
| 2017-03-02 | 재확인 | Wedbush | Outperform |
| 2016-10-04 | 개시 | Piper Jaffray | Overweight |
| 2015-12-22 | 개시 | Canaccord Genuity | Buy |
| 2015-08-05 | 재확인 | MLV & Co | Buy |
| 2015-02-12 | 재확인 | Oppenheimer | Outperform |
| 2015-01-28 | 재확인 | MLV & Co | Buy |
| 2014-07-11 | 개시 | Oppenheimer | Outperform |
모두보기
Xencor Inc 주식(XNCR)의 최신 뉴스
XENCOR Maintains Buy Rating -- Price Target Lowered to $27.00 by Truist Securities - GuruFocus
XNCRXencor Inc Revenue Breakdown - Finviz
Enterprise value to revenue forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Price to earnings forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Price to sales forward of Xencor, Inc. – TRADEGATE:XE9 - TradingView
Liquidity Mapping Around (XNCR) Price Events - Stock Traders Daily
XE9 Forecast — Price Target — Prediction for 2027 - TradingView
Xencor, Inc. Actuals & Estimates (FWB:XE9) - TradingView
XNCR Forecast — Price Target — Prediction for 2027 - TradingView
Xencor, Inc. Actuals & Estimates (NASDAQ:XNCR) - TradingView
Price to book forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Xencor Inc (XNCR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xencor director Ellen Feigal sells $89,369 in company stock By Investing.com - Investing.com South Africa
Insider Sell Alert: Ellen Feigal Sells Shares of Xencor Inc (XNC - GuruFocus
Form 4 Xencor Inc For: 22 June By Investing.com - Investing.com Nigeria
Xencor director Ellen Feigal sells $89,369 in company stock - Investing.com
Xencor (XNCR) director’s 10b5-1 sale covers 6,843 common shares - Stock Titan
XNCR Q1 2026 Earnings: Deep Loss Miss Weighs on SentimentProfit Warning Alert - dars.gov.et
Xencor, Inc. Files 8-K: Company Details, Stock Info, and Executive Plan Updates for 2026 - Minichart
Xencor Shareholders Approve Directors, Incentive Plan Amendments - TipRanks
Why (XNCR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Xencor (NASDAQ: XNCR) investors back 4M-share equity plan boost and all proposals - Stock Titan
Xencor Inc (XNCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
[144] Xencor Inc SEC Filing - Stock Titan
Insider Sell Alert: Richard Ranieri Sells Shares of Xencor Inc (XNCR) - GuruFocus
Xencor Inc (XNCR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Xencor Inc (XNCR) Institutional Confidence - TradingKey
Xencor Inc (XNCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Xencor Inc (XNCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xencor Inc (XNCR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Xencor Inc (XNCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xencor Inc (XNCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Director at Xencor (XNCR) sells 7,527 shares under 10b5-1 plan - Stock Titan
Xencor (XNCR) director sells 5,474 shares under Rule 10b5-1 plan - Stock Titan
Xencor (XNCR) director Ranieri sells 5,474 shares under 10b5-1 plan - Stock Titan
Planned share sale by Xencor (XNCR) director under Rule 10b5-1 plan - Stock Titan
Barclays Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Xencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets Caution - Yahoo Finance
Xencor Inc Stock (US98401F1057): Analyst Views In Focus After Recent Collaboration Momentum - AD HOC NEWS
Understanding Momentum Shifts in (XNCR) - Stock Traders Daily
Xencor (XNCR) Slides 2% as Biotech Sentiment Weakens — Support TestedTRIN Signal - newsline.com
Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial - MSN
Xencor Inc stock (US98401F1057): shares react to Monjuvi first-line lymphoma update and recent Q1 20 - AD HOC NEWS
XNCR Technical Analysis & Stock Price Forecast - Intellectia AI
XNCR Q1 2026 Earnings: Deep Loss Miss as Pipeline Biotech Faces Market SkepticismInterim Report - The Legal Advocate
XNCR Q1 2026 Earnings: Significant EPS Miss Amidst Clinical Development ProgressAnnual Report - newsline.com
XNCR Q1 2026 Earnings: Deeper-than-Expected Loss Highlights Persistent R&D InvestmentEarnings Revision Upgrade - newsline.com
Xencor Inc stock (US98401F1057): shares trade around recent lows as investors digest pipeline and va - AD HOC NEWS
Avoiding Lag: Real-Time Signals in (XNCR) Movement - Stock Traders Daily
Xencor Inc (XNCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.67%
3.59%
자본화:
|
볼륨(24시간):